Literature DB >> 1655683

Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells.

E O Long1, S Rosen-Bronson, D R Karp, M Malnati, R P Sekaly, D Jaraquemada.   

Abstract

cDNA expression vectors with several useful features were constructed. First, the long terminal repeat of Rous sarcoma virus was used as a promoter to obtain high levels of expression in various cells of human and mouse origin. Second, cis-linked expression units that confer resistance either to mycophenolic acid or the neomycin analog G418 were inserted to facitate the isolation of transfected cells expressing the cDNA of interest. Third, by replicating in simian COS cells, these vectors can be used for efficient transient expression. cDNA fragments encoding the DR alpha or DR beta chains of human class II major histocompatibility complex antigens were inserted into these vectors and high levels of cell surface HLA-DR antigen were obtained after cotransfection into mouse and human fibroblasts. These vectors were also successfully used to correct the inability of a class II-negative B cell line, derived from a patient with a congenital immunodeficiency, to present peptide antigen to DR-restricted T cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655683     DOI: 10.1016/0198-8859(91)90092-n

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  43 in total

1.  Alternative proteolytic processing of mouse mammary tumor virus superantigens.

Authors:  F Denis; N H Shoukry; M Delcourt; J Thibodeau; N Labrecque; H McGrath; J S Munzer; N G Seidah; R P Sékaly
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor.

Authors:  K M Haan; W W Kwok; R Longnecker; P Speck
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Distinct binding sites on HLA-DR for invariant chain and staphylococcal enterotoxins.

Authors:  D R Karp; R N Jenkins; E O Long
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

4.  Human immunodeficiency virus type 1 Rev activation can be achieved without Rev-responsive element RNA if Rev is directed to the target as a Rev/MS2 fusion protein which tethers the MS2 operator RNA.

Authors:  S Venkatesan; S M Gerstberger; H Park; S M Holland; Y Nam
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

5.  Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.

Authors:  Xueqing Lu; Shuzhen Wu; Catherine E Blackwell; Robert E Humphreys; Eric von Hofe; Minzhen Xu
Journal:  Immunology       Date:  2006-11-20       Impact factor: 7.397

6.  A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site.

Authors:  A R Welch; A S Woods; L M McNally; R J Cotter; W Gibson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

7.  Molecular characterization of the putative T-cell receptor cavity of the superantigen staphylococcal enterotoxin B.

Authors:  C Garcia; C Briggs; L Zhang; L Guan; J L Gabriel; T J Rogers
Journal:  Immunology       Date:  1998-06       Impact factor: 7.397

8.  Human T-cell clones to the 70-kilodalton heat shock protein of Mycobacterium leprae define mycobacterium-specific epitopes rather than shared epitopes.

Authors:  E Adams; A Basten; S Rodda; W J Britton
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

9.  The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity.

Authors:  R Cantin; J F Fortin; G Lamontagne; M Tremblay
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

10.  Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.

Authors:  Xuede Lin; Xiaojian Wang; Haley L Capek; Laura C Simone; Amit Tuli; Chantey R Morris; Adrian J Reber; Joyce C Solheim
Journal:  Cancer Immunol Immunother       Date:  2008-10-01       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.